Combination of PPARgamma activation and temozolomide chemotherapy leads to antineoplastic effects in glioma cells

Gliomas are the most common primary tumors of the central nervous system. They initially respond to radiotherapy and to a lesser extent to chemotherapy, however, they invariably recur. Despite considerable research efforts no curative therapy exists and the majority of patients die within the first year after diagnosis. Peroxisome proliferator-activated receptors (PPARs) belong to the group of nuclear hormone receptors. To date, a number of different synthetic ligands of PPARs has been developed, including the group of thiazolidinediones (TZDs), of which some are already in clinical use as oral antidiabetic drug…